STEP trial programme: difference between revisions
Diff·revision 5 → 6·10:56, 14 Aug 2024
Difference between revision 5 and revision 6 of STEP trial programme. 3 lines changed; the page grew by 353 bytes.
| Revision 5 — 20:18, 6 Aug 2024 Chromatokid (talk) state that the trial has reported but is not yet peer-reviewed 2,859 bytes +516 | Revision 6 — 10:56, 14 Aug 2024 DataTableDunja (talk) give the primary endpoint as pre-specified, not as reported 3,212 bytes +353 | ||
|---|---|---|---|
| 11 | STEP 1, the largest and most cited, randomised 1,961 adults with obesity and without diabetes to semaglutide 2.4 mg or placebo for 68 weeks, both arms receiving lifestyle intervention. Mean weight change was −14.9% on active treatment and −2.4% on placebo.{{r|wilding2021}} | 11 | STEP 1, the largest and most cited, randomised 1,961 adults with obesity and without diabetes to semaglutide 2.4 mg or placebo for 68 weeks, both arms receiving lifestyle intervention. Mean weight change was −14.9% on active treatment and −2.4% on placebo.{{r|wilding2021}} |
| 12 | 12 | ||
| + | 13 | The placebo arm is essential to interpreting that figure. Both arms received counselling on diet and physical activity, so the −2.4% is not a no-treatment baseline, and the [[Placebo-adjusted effect|placebo-adjusted difference]] of about 12.4 percentage points is the quantity attributable to the drug.{{r|davies2021}} | |
| + | 14 | ||
| 13 | == The constituent trials == | 15 | == The constituent trials == |
| 14 | | Trial | Population | Comparison | Weight change, active vs comparator | | 16 | | Trial | Population | Comparison | Weight change, active vs comparator | |
| ⋮ | ⋮ | ||
| 33 | [[Category:Clinical trial programmes]] | 35 | [[Category:Clinical trial programmes]] |
| 34 | [[Category:Obesity trials]] | 36 | [[Category:Obesity trials]] |
| + | 37 | [[Category:Clinical evidence]] | |
| 35 | 38 |